# MAGEA9

## Overview
MAGEA9 is a gene that encodes the protein MAGE family member A9, which belongs to the melanoma antigen (MAGE) family, specifically classified under type I MAGE genes. These genes are located on the X chromosome and are characterized by their expression in various cancers and restricted expression in normal tissues such as the testis and placenta (Artamonova2004Evolution). The MAGEA9 protein contains a conserved MAGE homology domain (MHD), which is essential for protein-protein interactions and plays a role in the degradation of tumor suppressor proteins like p53 (Alsalloum2023The). MAGEA9 is implicated in cancer progression, with its expression linked to poor prognosis in several cancers, including hepatocellular carcinoma and bladder cancer (Picard2007MAGE‐A9; Gu2014High). Due to its tumor-specific expression, MAGEA9 is considered a potential target for cancer immunotherapy, although therapeutic success has been limited (Alsalloum2023The).

## Structure
The MAGEA9 protein is a member of the MAGE (melanoma antigen) family, specifically classified under type I MAGE genes, which are located on the X chromosome. The primary structure of MAGEA9 consists of 315 amino acids, with the MAGE homology domain (MHD) beginning at residue 108 (Barker2002The). This domain is a conserved region of approximately 170 amino acids, characterized by a tandem-winged helix motif, which is crucial for protein-protein interactions (Li2021Pathogenicity; Alsalloum2023The).

The secondary structure of the MHD is predicted to include α-helical and β-sheet structures (Barker2002The). The MAGEA9 gene is part of a sublocus formed by an inverted duplication and is closely related to MAGE-A2, with only a few nucleotide substitutions between them (Artamonova2004Evolution). The gene's exon-intron structure includes a single protein-coding exon preceded by several noncoding exons, with alternative splicing leading to different isoforms (Artamonova2004Evolution).

MAGEA9 is expressed in various cancers and testis, with weak expression in other tissues like the placenta (Artamonova2004Evolution). The expression and function of MAGEA9 in cancer are influenced by its interactions with other proteins, such as E3 ubiquitin ligase, which are involved in the degradation of tumor suppressor proteins like p53 (Alsalloum2023The).

## Clinical Significance
MAGEA9, a member of the melanoma-associated antigen family, is implicated in various cancers due to its abnormal expression in tumor tissues. High expression of MAGEA9 is associated with poor prognosis in several cancers, including hepatocellular carcinoma (HCC), where it correlates with unfavorable disease-free and overall survival. It is linked to aggressive tumor characteristics such as lymph node metastasis and portal vein invasion in HCC (Gu2014High). In bladder cancer, MAGEA9 is frequently expressed in both superficial and invasive tumors, with higher expression levels associated with higher-grade tumors and progression (Bergeron2009High; Picard2007MAGE‐A9).

MAGEA9 expression is also significant in lung, gastrointestinal, ovarian, and breast cancers, where it is associated with poor clinical outcomes (Poojary2020Prognostic). The gene's expression is typically restricted to the testis and placenta in normal tissues, but its aberrant expression in cancers contributes to tumorigenic activities such as growth, proliferation, and metastasis (Poojary2020Prognostic). MAGEA9's role in cancer progression and its tumor-specific expression make it a potential target for cancer immunotherapy, although therapeutic success has been limited (Alsalloum2023The).


## References


[1. (Li2021Pathogenicity) Sanyan Li, Xiang Shi, Jingping Li, and Xianrong Zhou. Pathogenicity of the mage family (review). Oncology Letters, October 2021. URL: http://dx.doi.org/10.3892/ol.2021.13105, doi:10.3892/ol.2021.13105. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2021.13105)

[2. (Barker2002The) Philip A. Barker and Amir Salehi. The mage proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. Journal of Neuroscience Research, 67(6):705–712, February 2002. URL: http://dx.doi.org/10.1002/jnr.10160, doi:10.1002/jnr.10160. This article has 243 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jnr.10160)

[3. (Artamonova2004Evolution) Irena I. Artamonova and Mikhail S. Gelfand. Evolution of the exon–intron structure and alternative splicing of the mage-a family of cancer/testis antigens. Journal of Molecular Evolution, 59(5):620–631, November 2004. URL: http://dx.doi.org/10.1007/s00239-004-2654-3, doi:10.1007/s00239-004-2654-3. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00239-004-2654-3)

[4. (Picard2007MAGE‐A9) Valérie Picard, Alain Bergeron, Hélène LaRue, and Yves Fradet. Mage‐a9 mrna and protein expression in bladder cancer. International Journal of Cancer, 120(10):2170–2177, March 2007. URL: http://dx.doi.org/10.1002/ijc.22282, doi:10.1002/ijc.22282. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.22282)

[5. (Alsalloum2023The) Alaa Alsalloum, Julia Shevchenko, and Sergey Sennikov. The melanoma-associated antigen family a (mage-a): a promising target for cancer immunotherapy? Cancers, 15(6):1779, March 2023. URL: http://dx.doi.org/10.3390/cancers15061779, doi:10.3390/cancers15061779. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15061779)

[6. (Bergeron2009High) Alain Bergeron, Valérie Picard, Hélène LaRue, Francois Harel, Hélène Hovington, Louis Lacombe, and Yves Fradet. High frequency of mage‐a4 and mage‐a9 expression in high‐risk bladder cancer. International Journal of Cancer, 125(6):1365–1371, July 2009. URL: http://dx.doi.org/10.1002/ijc.24503, doi:10.1002/ijc.24503. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.24503)

[7. (Poojary2020Prognostic) Manish Poojary, Padacherri Vethil Jishnu, and Shama Prasada Kabekkodu. Prognostic value of melanoma-associated antigen-a (mage-a) gene expression in various human cancers: a systematic review and meta-analysis of 7428 patients and 44 studies. Molecular Diagnosis &amp; Therapy, 24(5):537–555, June 2020. URL: http://dx.doi.org/10.1007/s40291-020-00476-5, doi:10.1007/s40291-020-00476-5. This article has 20 citations.](https://doi.org/10.1007/s40291-020-00476-5)

[8. (Gu2014High) Xuefeng Gu, Maoying Fu, Zhijun Ge, Feng Zhan, Yuqin Ding, Huihui Ni, Wei Zhang, Yanfang Zhu, Xiaojun Tang, Lin Xiong, Jiang Li, Liang Qiu, Yuan Mao, and Jin Zhu. High expression of mage-a9 correlates with unfavorable survival in hepatocellular carcinoma. Scientific Reports, October 2014. URL: http://dx.doi.org/10.1038/srep06625, doi:10.1038/srep06625. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep06625)